
News|Videos|July 27, 2023
Experts Present Background on Long-Term Safety Study of Upadacitinib for AD
Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
The Weekly Roundup: December 8-12
5



































